Efficacy and Safety of Subcutaneous Tabalumab, a Monoclonal Antibody to B-Cell Activating Factor, in Patients With Systemic Lupus Erythematosus: Results From ILLUMINATE-2, a 52-Week, Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases - United Kingdom

doi 10.1136/annrheumdis-2015-207654